Lista de obras -

A case control study of syngeneic transplantation versus autologous transplantation for multiple myeloma: two decades of experiences from a single center

artículo científico publicado en 2017

A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid

artículo científico publicado en 2011

A randomized phase II trial of fludarabine/melphalan 100 versus fludarabine/melphalan 140 followed by allogeneic hematopoietic stem cell transplantation for patients with multiple myeloma

artículo científico publicado en 2013

African Americans with translocation t(11;14) have superior survival after autologous hematopoietic cell transplantation for multiple myeloma in comparison with Whites in the United States

scientific article published on 23 September 2020

Age no bar: A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma

scientific article published on 23 September 2020

Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity.

artículo científico publicado en 2013

Autologous Hematopoietic Stem Cell Transplantation in Dialysis-Dependent Myeloma Patients

artículo científico publicado en 2015

Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin's lymphoma: effect of the specific high-dose chemotherapy regimen on outcome.

artículo científico publicado en 2012

Better allele-level matching improves transplant-related mortality after double cord blood transplantation.

artículo científico publicado en 2015

Chromosome 8q24.1/c-MYC abnormality: a marker for high-risk myeloma

artículo científico publicado en 2014

Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia: Long-Term Study Results

artículo científico publicado en 2016

Comparison of Outcomes of Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Three Different Conditioning Regimens

scientific article published on 11 January 2019

Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial

scientific article published on 22 March 2019

Cord blood natural killer cells exhibit impaired lytic immunological synapse formation that is reversed with IL-2 exvivo expansion.

artículo científico publicado en 2010

Cord-blood engraftment with ex vivo mesenchymal-cell coculture

artículo científico publicado en 2012

Cytogenetics and Blast Count Determine Transplant Outcomes in Patients with Active Acute Myeloid Leukemia

artículo científico publicado en 2020

Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma.

scientific article published on 20 May 2016

Double umbilical cord blood transplant is effective therapy for relapsed or refractory Hodgkin lymphoma

artículo científico publicado en 2015

Durable remission with salvage second autotransplants in patients with multiple myeloma

artículo científico publicado en 2011

Durable responses after donor lymphocyte infusion for patients with residual multiple myeloma following non-myeloablative allogeneic stem cell transplant

artículo científico publicado en 2012

Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation

artículo científico publicado en 2015

Estimation of minimally important differences and responder definitions for EORTC QLQ-MY20 scores in multiple myeloma patients

artículo científico publicado en 2019

Ex Vivo Mesenchymal Precursor Cell-Expanded Cord Blood Transplantation after Reduced-Intensity Conditioning Regimens Improves Time to Neutrophil Recovery.

artículo científico publicado en 2017

Ex vivo graft purging and expansion of autologous blood progenitor cell products from patients with multiple myeloma

artículo científico publicado en 2011

Feasibility of autologous hematopoietic stem cell transplant in patients aged ≥70 years with multiple myeloma

artículo científico publicado en 2011

Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial

artículo científico publicado en 2018

Fucosylation with fucosyltransferase VI or fucosyltransferase VII improves cord blood engraftment

artículo científico publicado en 2013

High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan

artículo científico publicado en 2017

High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignancies

artículo científico publicado en 2012

High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomes

scientific article published on 22 July 2018

Higher Stem Cell Dose Infusion after Intensive Chemotherapy Does Not Improve Symptom Burden in Older Patients with Multiple Myeloma and Amyloidosis

artículo científico publicado en 2015

Histologic Grade 1 Is Associated With Increased Nonrelapsed Mortality in Lower Gastrointestinal Graft Versus Host Disease

artículo científico publicado en 2017

Impact of Hepatitis B Core Antibody Seropositivity on the Outcome of Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma

artículo científico publicado en 2017

Impact of t(11;14)(q13;q32) on the outcome of autologous hematopoietic cell transplantation in multiple myeloma.

artículo científico publicado en 2013

Incidence and natural history of pure red cell aplasia in major ABO-mismatched haematopoietic cell transplantation

artículo científico publicado en 2013

Inpatient vs outpatient autologous hematopoietic stem cell transplantation for multiple myeloma.

artículo científico publicado en 2017

Long-term follow-up of patients receiving allogeneic stem cell transplant for chronic lymphocytic leukaemia: mixed T-cell chimerism is associated with high relapse risk and inferior survival

artículo científico publicado en 2017

Measuring cardiopulmonary complications of carfilzomib treatment and associated risk factors using the SEER-Medicare database

artículo científico publicado en 2019

Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma.

artículo científico publicado en 2017

Outcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation

artículo científico publicado en 2015

Outcomes in patients with multiple myeloma with TP53 deletion after autologous hematopoietic stem cell transplant ⬇️

artículo científico publicado en 2016

Patient age and number of apheresis days may predict development of secondary myelodysplastic syndrome and acute myelogenous leukemia after high-dose chemotherapy and autologous stem cell transplantation for lymphoma

artículo científico publicado en 2017

Pentostatin therapy for steroid-refractory acute graft versus host disease: identifying those who may benefit.

artículo científico publicado en 2017

Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma

artículo científico publicado en 2017

Phase I study protocol: NKTR-255 as monotherapy or combined with daratumumab or rituximab in hematologic malignancies

artículo científico publicado en 2021

Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hematological Malignancies.

artículo científico publicado en 2015

Predictors of inferior clinical outcome in patients with standard-risk multiple myeloma.

artículo científico publicado en 2016

Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma

artículo científico publicado en 2012

Primary plasma cell leukemia: autologous stem cell transplant in an era of novel induction drugs

artículo científico publicado en 2018

Prolonged survival with a longer duration of maintenance lenalidomide after autologous hematopoietic stem cell transplantation for multiple myeloma

artículo científico publicado en 2016

Pure Red Cell Aplasia in Major ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with Severe Pancytopenia

artículo científico publicado en 2016

Regulatory B cells are enriched within the IgM memory and transitional subsets in healthy donors but are deficient in chronic GVHD

artículo científico publicado en 2014

Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation

artículo científico publicado en 2016

Short-term cardiac toxicity of autologous hematopoietic stem cell transplant for multiple myeloma

artículo científico publicado en 2014

Specific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantation.

artículo científico publicado en 2016

Utility of a patient-reported outcome in measuring functional impairment during autologous stem cell transplant in patients with multiple myeloma

artículo científico publicado en 2017

Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas.

artículo científico publicado en 2015

Lista de obras de

A case control study of syngeneic transplantation versus autologous transplantation for multiple myeloma: two decades of experiences from a single center

A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid

A randomized phase II trial of fludarabine/melphalan 100 versus fludarabine/melphalan 140 followed by allogeneic hematopoietic stem cell transplantation for patients with multiple myeloma

African Americans with translocation t(11;14) have superior survival after autologous hematopoietic cell transplantation for multiple myeloma in comparison with Whites in the United States

Age no bar: A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma

Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity.

Autologous Hematopoietic Stem Cell Transplantation in Dialysis-Dependent Myeloma Patients

Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin's lymphoma: effect of the specific high-dose chemotherapy regimen on outcome.

Better allele-level matching improves transplant-related mortality after double cord blood transplantation.

Chromosome 8q24.1/c-MYC abnormality: a marker for high-risk myeloma

Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia: Long-Term Study Results

Comparison of Outcomes of Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Three Different Conditioning Regimens

Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial

Cord blood natural killer cells exhibit impaired lytic immunological synapse formation that is reversed with IL-2 exvivo expansion.

Cord-blood engraftment with ex vivo mesenchymal-cell coculture

Cytogenetics and Blast Count Determine Transplant Outcomes in Patients with Active Acute Myeloid Leukemia

Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma.

Double umbilical cord blood transplant is effective therapy for relapsed or refractory Hodgkin lymphoma

Durable remission with salvage second autotransplants in patients with multiple myeloma

Durable responses after donor lymphocyte infusion for patients with residual multiple myeloma following non-myeloablative allogeneic stem cell transplant

Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation

Estimation of minimally important differences and responder definitions for EORTC QLQ-MY20 scores in multiple myeloma patients

Ex Vivo Mesenchymal Precursor Cell-Expanded Cord Blood Transplantation after Reduced-Intensity Conditioning Regimens Improves Time to Neutrophil Recovery.

Ex vivo graft purging and expansion of autologous blood progenitor cell products from patients with multiple myeloma

Feasibility of autologous hematopoietic stem cell transplant in patients aged ≥70 years with multiple myeloma

Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial

Fucosylation with fucosyltransferase VI or fucosyltransferase VII improves cord blood engraftment

High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan

High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignancies

High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomes

Higher Stem Cell Dose Infusion after Intensive Chemotherapy Does Not Improve Symptom Burden in Older Patients with Multiple Myeloma and Amyloidosis

Histologic Grade 1 Is Associated With Increased Nonrelapsed Mortality in Lower Gastrointestinal Graft Versus Host Disease

Impact of Hepatitis B Core Antibody Seropositivity on the Outcome of Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma

Impact of t(11;14)(q13;q32) on the outcome of autologous hematopoietic cell transplantation in multiple myeloma.

Incidence and natural history of pure red cell aplasia in major ABO-mismatched haematopoietic cell transplantation

Inpatient vs outpatient autologous hematopoietic stem cell transplantation for multiple myeloma.

Long-term follow-up of patients receiving allogeneic stem cell transplant for chronic lymphocytic leukaemia: mixed T-cell chimerism is associated with high relapse risk and inferior survival

Measuring cardiopulmonary complications of carfilzomib treatment and associated risk factors using the SEER-Medicare database

Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma.

Outcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation

Outcomes in patients with multiple myeloma with TP53 deletion after autologous hematopoietic stem cell transplant ⬇️

Patient age and number of apheresis days may predict development of secondary myelodysplastic syndrome and acute myelogenous leukemia after high-dose chemotherapy and autologous stem cell transplantation for lymphoma

Pentostatin therapy for steroid-refractory acute graft versus host disease: identifying those who may benefit.

Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma

Phase I study protocol: NKTR-255 as monotherapy or combined with daratumumab or rituximab in hematologic malignancies

Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hematological Malignancies.

Predictors of inferior clinical outcome in patients with standard-risk multiple myeloma.

Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma

Primary plasma cell leukemia: autologous stem cell transplant in an era of novel induction drugs

Prolonged survival with a longer duration of maintenance lenalidomide after autologous hematopoietic stem cell transplantation for multiple myeloma

Pure Red Cell Aplasia in Major ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with Severe Pancytopenia

Regulatory B cells are enriched within the IgM memory and transitional subsets in healthy donors but are deficient in chronic GVHD

Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation

Short-term cardiac toxicity of autologous hematopoietic stem cell transplant for multiple myeloma

Specific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantation.

Utility of a patient-reported outcome in measuring functional impairment during autologous stem cell transplant in patients with multiple myeloma

Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas.